# NewDays: Seattle AI Profile — Product, Footprint & Verified Record

- **Canonical Web Article:** https://tygartmedia.com/newdays-seattle-wa-ai-profile/
- **Profile Brief (PDF):** https://tygartmedia.com/wp-content/uploads/2026/11/newdays-seattle-wa-ai-profile.pdf
- **Markdown Twin:** https://tygartmedia.com/wp-content/uploads/2026/11/newdays-seattle-wa-ai-profile.md
- **Snapshot Infographic:** https://tygartmedia.com/wp-content/uploads/2026/11/newdays-seattle-wa-ai-profile-infographic.png
- **Verified Date:** 2026-11-19

> **Sourced Baseline:** As of November 19, 2026, NewDays operates independently from Seattle, Washington, delivering Medicare-covered telehealth cognitive care paired with its AI companion Sunny across Washington, California, Florida, Texas, New York, and Nevada. Backed by $16M in total Seed funding led by Madrona Venture Group and General Catalyst, the 32-person company is running a randomized controlled trial with Kaiser Permanente in California.

## Verified Company Record

| Field | Verified Record (As of Nov 19, 2026) |
| :--- | :--- |
| **Company** | NewDays |
| **Official Website** | https://www.newdays.ai/ |
| **Washington HQ** | Seattle, WA |
| **Other WA Footprint** | Seattle (206) 801-1621 patient support line; Washington is one of six active telehealth care states |
| **Founded** | 2024 |
| **Founders / Leadership** | Babak Parviz (Co-Founder & CEO), Daniel Kelly (Co-Founder & Chief Innovation Officer), Alex Bahar-Fuchs (Director of Neuropsychology), Daniel Fenton (Head of Neuropsychological Services) |
| **Stage** | Seed |
| **Announced Funding** | $16M total Seed ($7M Sep 2025 + $4.5M Oct 2025 + final tranche closing Sep 2026) |
| **Team Size** | 32 (Fall 2026 GeekWire 200) |
| **Primary Ecosystem Ties** | Madrona Venture Group (Seed co-lead), GeekWire 200 (Fall 2026), Amazon executive alumni founders, GeekWire coverage (2025–2026) |

## What NewDays Builds

NewDays develops a clinician-supervised, AI-assisted cognitive treatment platform delivered at home for older adults living with mild cognitive impairment (MCI) or mild dementia. Its care model pairs once- or twice-monthly telehealth sessions with licensed human cognitive clinicians alongside unlimited personalized conversations and exercises led by Sunny, an AI companion and brain trainer.

As reported by [GeekWire at its September 2025 launch](https://www.geekwire.com/2025/amazon-and-google-alums-land-7m-to-build-a-personal-ai-therapist-for-people-with-dementia/), NewDays adapts behavioral interventions studied in the Internet-Based Conversational Engagement Clinical Trial (I-CONECT), a virtual conversational therapy model led by a Harvard Medical School researcher. CEO Babak Parviz explained that NewDays assigns roughly 90% to 95% of routine conversational practice—spanning cognitive stimulation, cognitive training, and cognitive rehabilitation—to AI while human clinicians supervise treatment plans to keep care scalable.

- Hybrid care delivery: Combines licensed human telehealth clinicians (1–2 visits per month) with daily AI-guided brain training between appointments.
- Sunny AI companion: Engages patients in personalized discussions, memory exercises, reminiscence, and language or reasoning games tailored to individual interests.
- Evidence-based protocol lineage: Built on behavioral therapy concepts from the I-CONECT clinical study aimed at slowing cognitive decline and reducing isolation.
- Caregiver utility: Designed to practice real-world conversational confidence rather than replace human relationships, while giving family care partners periodic respite.

## Washington Footprint and Leadership

NewDays is headquartered in Seattle, Washington, operating its patient support line on a local (206) 801-1621 Pacific Time number published on [newdays.ai](https://www.newdays.ai/) and employing 32 people according to the [Fall 2026 GeekWire 200](https://www.geekwire.com/geekwire-200/). The company was founded in 2024 by two veteran technology executives from Amazon and Google X who both had personal family experience with dementia.

Clinical oversight is embedded alongside technology leadership, with dedicated neuropsychology leaders managing clinical delivery and assessment protocols.

- Babak Parviz (Co-Founder & CEO): Former Vice President at Amazon leading the Grand Challenge healthcare and innovation initiative; previously at Google X where he led the Google Glass team.
- Daniel Kelly (Co-Founder & Chief Innovation Officer): Former engineering leader at Amazon and Google X.
- Clinical leadership: Alex Bahar-Fuchs serves as Director of Neuropsychology and Daniel Fenton serves as Head of Neuropsychological Services.
- Local team scale: Recorded 32 employees in the Fall 2026 GeekWire 200 update (previously listed at No. 190 in October 2025 GeekWire coverage).

## Products, Users, and Public Traction

By [September 2, 2026](https://www.geekwire.com/2026/newdays-brings-its-ai-driven-dementia-care-platform-to-nevada-expands-seed-round-to-16m/), NewDays had expanded its clinical telehealth availability to six states: Washington, California, Florida, Texas, New York, and Nevada. The program is covered by traditional Medicare while the company pursues in-network agreements with private insurers and Medicare Advantage plans. Prospective participants can try Sunny for free, schedule a free 20-minute suitability assessment, or pay $150 out-of-pocket per clinical session. While NewDays confirmed generating revenue in October 2025, it has not publicly disclosed total enrolled patient counts or revenue figures.

Clinical validation is advancing from small cohort reporting toward formal controlled testing. At the July 2026 Alzheimer's Association International Conference (AAIC), NewDays presented data from a 24-patient cohort (12 with dementia and 12 with other cognitive impairment) performing above historical decline curves—equivalent to roughly 18 months of preserved cognitive function. To test clinical efficacy more rigorously, NewDays is running a randomized controlled trial (RCT) with Kaiser Permanente in California. This profile summarizes public reporting and company disclosures for informational purposes only and is not medical advice.

- Geographic reach and payer access: Active in WA, CA, FL, TX, NY, and NV; covered by traditional Medicare, with $150 out-of-pocket option per clinical visit (Sep 2, 2026 GeekWire).
- Kaiser Permanente research trial: Currently running a randomized controlled trial with Kaiser Permanente in California to evaluate clinical outcomes.
- AAIC 2026 cohort summary (company-reported / 24-patient study): Reported ~18 months (1.5 years) estimated delay in dementia symptom progression vs. published no-treatment decline; newdays.ai cites 75% improved cognitive scores (ACE-III) and stable/improved depression (79%, GDS-15) and anxiety (67%, GAI) across patients tracked 3 to 13 months.
- Early pilot feedback: A 2025 pilot spanning more than 1,000 users in WA, CA, and FL reported a 4.5 out of 5 approval rating (Sep 3, 2025 GeekWire).

## Funding, Stage, and Place in Washington's AI Landscape

NewDays built its $16M total Seed financing across three disclosed milestones led by Seattle's Madrona Venture Group and General Catalyst. The startup emerged in September 2025 with a $7M initial Seed announcement, confirmed a [$4.5M addition in October 2025](https://www.geekwire.com/2025/newdays-raises-additional-4-5m-for-platform-that-uses-generative-ai-to-treat-people-with-dementia/) bringing cumulative funding to $11.5M, and closed the expanded Seed round at $16M total alongside its Nevada expansion in September 2026.

Within Washington's AI landscape, NewDays exemplifies Seattle's growing clinician-in-the-loop health AI cohort, pairing former Amazon leadership with local institutional venture backing from Madrona to tackle Medicare-reimbursed chronic and geriatric care.

- Seed trajectory: $7M initial announcement (Sep 2025), $4.5M extension (Oct 2025, reaching $11.5M), and final close bringing total Seed capital to $16M (Sep 2026).
- Lead investors: Co-led by Seattle-based Madrona Venture Group and General Catalyst.
- Ecosystem engagement: Co-founders Parviz and Kelly appeared on Madrona's 'Founded & Funded' podcast with Managing Director Tim Porter; company is tracked on the GeekWire 200.
- Independent status: Remains a privately held Seed-stage company with no Series A or acquisition announced through November 19, 2026.

## Related Washington AI Profiles & Tygart Media Context

- [PreemptiveAI — Seattle Physiological Foundation Models & Health Profile](https://tygartmedia.com/preemptiveai-seattle-wa-ai-profile/)
- [Aria — Seattle Behavioral Health Practice AI Profile](https://tygartmedia.com/aria-seattle-wa-ai-profile/)
- [Tibbling Technologies — Redmond Multimodal NeuroAI & Health Tech Profile](https://tygartmedia.com/tibbling-technologies-redmond-wa-ai-profile/)
- [Is Your Voice Assistant a Brain, or Just a Router?](https://tygartmedia.com/is-your-voice-assistant-a-brain-or-just-a-router/)

## Verified Primary Sources

- [NewDays Official Website](https://www.newdays.ai/)
- [GeekWire — NewDays Expands to Nevada & Closes $16M Seed (Sep 2, 2026)](https://www.geekwire.com/2026/newdays-brings-its-ai-driven-dementia-care-platform-to-nevada-expands-seed-round-to-16m/)
- [GeekWire — NewDays Adds $4.5M Seed Extension (Oct 9, 2025)](https://www.geekwire.com/2025/newdays-raises-additional-4-5m-for-platform-that-uses-generative-ai-to-treat-people-with-dementia/)
- [GeekWire — NewDays $7M Launch Coverage (Sep 3, 2025)](https://www.geekwire.com/2025/amazon-and-google-alums-land-7m-to-build-a-personal-ai-therapist-for-people-with-dementia/)
- [GeekWire 200 Index](https://www.geekwire.com/geekwire-200/)
- [NewDays Terms of Use](https://app.newdays.ai/legal/terms-of-use)

## Frequently Asked Questions

### How does NewDays combine human clinicians with its AI companion Sunny?

NewDays pairs once- or twice-monthly telehealth visits with licensed cognitive clinicians alongside unlimited personalized conversations and exercises led by Sunny, an AI brain trainer. Clinicians oversee each patient's care plan while Sunny delivers between-session cognitive stimulation, training, and rehabilitation grounded in the I-CONECT research model.

### Where is NewDays available, and does Medicare cover treatment?

As of September 2026 GeekWire reporting, NewDays offers clinical services in six states: Washington, California, Florida, Texas, New York, and Nevada. The program is covered by traditional Medicare, with a free Sunny trial, a free 20-minute suitability assessment, and a $150 out-of-pocket per-session option while the company pursues additional private insurer and Medicare Advantage contracts.

### What clinical validation has NewDays shared so far?

At the July 2026 Alzheimer's Association International Conference, NewDays presented results from a 24-patient cohort showing cognitive scores exceeding historical decline curves by roughly 18 months. To validate efficacy in a controlled setting, NewDays is conducting a randomized controlled trial with Kaiser Permanente in California.
